Saroglitazar is the first and only dual PPAR α/γ agonist (Glitazars) which provides beneficial effects on lipid profile and glycemic control for the treatment of dyslipidemia and diabetes and is in clinical practice [17, 19–21, 34]. This evidence concerns the gene PPARA and metabolic syndrome.